New England Research & Management Inc. Has $1.41 Million Stock Position in Abbott Laboratories $ABT

New England Research & Management Inc. reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 45.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,334 shares of the healthcare product maker’s stock after selling 8,550 shares during the quarter. New England Research & Management Inc.’s holdings in Abbott Laboratories were worth $1,406,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories in the fourth quarter valued at about $32,000. Finally, JCIC Asset Management Inc. acquired a new stake in Abbott Laboratories in the first quarter valued at about $32,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $131.40 on Tuesday. The firm has a 50-day moving average of $130.36 and a 200-day moving average of $131.21. The company has a market cap of $228.70 billion, a P/E ratio of 16.47, a P/E/G ratio of 2.54 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. Evercore ISI raised their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. BTIG Research reduced their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Mizuho upped their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, July 16th. Finally, Leerink Partners started coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $144.47.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.